Integral Diagnostics Ltd · ASX:IDX
Integral Diagnostics — Shareholder Meeting (October 2025)
16 slides from Integral Diagnostics's shareholder meeting presentation, Oct 31, 2025
Slide 1: 2025 AGM – Managing Director & CEO Address and Presentation
Integral Diagnostics Limited 2025 Annual General Meeting – Managing Director & Chief Executive Officer Address and Presentation Thank you, Toby, and good morning everyone. It’s good to see you all, in the room and online. Vision and Values Our vision – to build a healthier world – is anchored in our
Slide 2: FY25 Results Overview
IDXt, has continued its rapid growth trajectory over the past year. The business unit currently engages 114 radiologists, and its reported revenue has grown consistently at a CAGR above 30%. The IDXt employee value proposition is compelling as it is able to provide radiologists with as much work as
Slide 3: Industry Fundamentals
During the financial year, we opened five new greenfield clinics, including Spotswood in Victoria, Glenorchy in Tasmania and Noosa in Queensland. We also relocated two clinics to new state of the art facilities; Ocean Grove in Victoria and the Smith Street Nuclear Medicine & Women’s Imaging Centre i
Slide 4: FY26 Strategy and Priorities
The top line on the chart represents Medicare benefits paid to DI providers, the bottom line on the chart represents the number of tests that were performed. The two lines are diverging due to the higher rate of increase in high acuity, high value tests like CT, MRI and PET-CT, relative to lower acu
Slide 5: Outlook for FY26 and Beyond
• Seasonally stronger 2H organic Operating EBITDA performance (2H ~53% vs 1H ~47% in recent years). In FY26 the 2H weighting is expected to be more pronounced driven by the ramp up of further de-regulation of MRI’s, the National Lung Cancer Screening Program and expansion from 1 November 2025 of the
Slide 6: Managing Director & CEO Presentation
MANAGING DIRECTOR & CEO PRESENTATION Dr Ian Kadish
Slide 7: Vision, Values and Purpose
VISION, VALUES AND PURPOSE OUR VISION a healthier world patients first Patients are at the heart of everything we do medical leadership Pursuing excellence in medical leadership through evidence-based care one team Our united team is our greatest asset create value We deliver sustainable value to al
Slide 8: IDX Today – Group Overview as at 30 June 2025
IDX TODAY – GROUP OVERVIEW AS AT 30 JUNE 2025 Geographic Market Victoria New South Wales Queensland Western Australia Tasmania South Australia New Zealand Metro and outer Western Sunshine Coast, Melbourne, Geelong, Ballarat, Rockhampton, Metro Perth, Albury, Lavington, Hobart, Launceston Adelaide Co
Slide 9: FY25 Results Overview
FY25 RESULTS OVERVIEW Consolidated Group (AUD $m) FY25 vs FY24 Solid revenue growth of 33.7% to $628.0m (including ~6-months contribution 1 from Capitol Health post-merger) Revenue(1) 628.0 33.7% (6.7% growth on an IDX standalone basis) Operating EBITDA(2) 126.5 38.3% 2 Improved operating EBITDA mar
Slide 10: FY25 Strategic Overview – Key Progress Update
FY25 STRATEGIC OVERVIEW – KEY PROGRESS UPDATE Capitol merger LFL organic growth Greenfield and inorganic growth Proceeding on plan with synergies to Continued evaluation and implementation Ongoing focus on driving organic growth ✓ exceed initial expectations and strategic ✓ and operational efficienc
Slide 11: IDX Well Positioned to Improve Access and Benefits for Patients
IDX WELL POSITIONED TO IMPROVE ACCESS AND BENEFITS FOR PATIENTS & CAPITALISE ON POSITIVE INDUSTRY FUNDAMENTALS ✓ Ageing population and earlier detection of disease drive demand for diagnostic services. ✓ Medicare DI benefits and services have recovered to be in line with long term trends. ✓ Medicare
Slide 12: DI Growth Rates Have Recovered to Be in Line with Long Term Trends
DI GROWTH RATES HAVE RECOVERED TO BE IN LINE WITH LONG TERM TRENDS: AUSTRALIA Industry growth rates, on a Industry Growth 12–month rolling basis, have 20.0% 12 month rolling growth rate by Service 12 month rolling growth rate by Benefit recovered to be in line with long term trends, driven by Medica
Slide 13: FY26 Strategy and Priorities
FY26 STRATEGY AND PRIORITIES Strategic Mergers & Strategy 1 Grow Existing Business and Margin 2 Acquisitions Drive organic Accelerate use of earnings growth, teleradiology, Drivers of including relentless Drive our digital and AI to Complete IDX and Capitol Health merger focus on radiologist environ
Slide 14: Outlook for FY26 and Beyond
OUTLOOK FOR FY26 AND BEYOND • IDX is a specialist, quality provider of diagnostic services and is well positioned to benefit from positive industry fundamentals, and to grow services strongly going forward. • The combined Group (IDX and Capitol) achieved 8.3% revenue growth in Australia YTD Septembe
Slide 15: Notes to Slides
NOTES TO SLIDES Slide 13: IDX Today – Group Overview 5. Of the 67 MRI machines, 61 are located in Australia 3. The impact of AASB 16: Leases on FY25 results was with 45 located in MM1 areas, including 16 partially an increment to pro forma Operating EBITDA of 1. Comprehensive sites include a range o
Slide 16: Disclaimer
DISCLAIMER 1. Some of the information contained in this 3. Past performance of IDX cannot be relied upon as 5. Reliance should not be placed on the information or presentation contains “forward-looking statements” an indicator of (and provides no guidance as to) the opinions contained in this presen
Integral Diagnostics — Shareholder Meeting (October 2025) on 6ix